- Home
- OTLK vs LPSN Comparison
OTLK vs LPSN Comparison
Compare OTLK & LPSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OTLK | LPSN |
|---|---|---|
| Founded | 2010 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.2M | 32.3M |
| IPO Year | 2016 | 2000 |
Fundamental Metrics
Financial Performance| Metric | OTLK | LPSN |
|---|---|---|
| Price | $0.23 | $2.22 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 1 |
| Target Price | ★ $2.50 | N/A |
| AVG Volume (30 Days) | ★ 4.3M | 141.3K |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.91 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $8,146,123.00 | ★ $249,838,000.00 |
| Revenue This Year | $1,430.98 | N/A |
| Revenue Next Year | $173.23 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.16 | $0.39 |
| 52 Week High | $3.39 | $7.54 |
Technical Indicators
Market Signals| Indicator | OTLK | LPSN |
|---|---|---|
| Relative Strength Index (RSI) | 42.17 | 36.62 |
| Support Level | $0.21 | $0.86 |
| Resistance Level | $0.29 | $2.78 |
| Average True Range (ATR) | 0.02 | 0.14 |
| MACD | -0.00 | -0.05 |
| Stochastic Oscillator | 24.53 | 15.87 |
Price Performance
Historical ComparisonAbout OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About LPSN LivePerson Inc.
LivePerson Inc is the enterprise leader in digital customer conversation. The Conversational Cloud, the Companies enterprise-class digital customer conversation platform, is trusted by the brands to accelerate their contact center transformation, orchestrate conversations across all channels, departments, and systems, increase agent productivity, and deliver more personalized, AI-empowered customer experiences. The company has a presence in the United States, Asia-Pacific, Latin America, and Europe.